Plus   Neg

Shell, Blackstone Mull $10 Bln Joint Bid For BHP's US Shale: Sky News

Oil behemoth Royal Dutch Shell plc (RDS-B,RDSB.L,RDSA.L,RDS-A) and US private equity giant Blackstone Group L.P. (BX) are mulling a 7.3 billion pound or $10 billion joint bid to acquire the American shale division of Anglo-Australian mining giant BHP Billiton plc (BHP.AX,BLT.L,BBL,BHP), according to a Sky News report.

The assets were put up for sale last summer by BHP amid pressure from activist investor Elliott Advisors. A deal is expected to be struck later this year.

The report stated that the proposed deal would be the largest takeover in which Shell has been involved since its 35 billion pounds purchase of BG Group in early 2016.

BHP has indicated that it will consider a separate stock market listing for the division if it fails to generate sufficient value from a trade sale. It also said this week that it would look at asset swaps as part of the disposal plan.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
In the age of social media, it takes mere hours for a company to suffer the backlash of of allegations of racism. For some companies, these incidents have hurt their bottom line and sullied their reputations. For others, they were a blip caused by clumsy if not altogether coincidental missteps. In... BJ's Wholesale Club Holdings Inc., which is planning a return to the public market, has set terms for its planned initial public offering or IPO. In a filing with the U.S. Securities and Exchange Commission, the warehouse club operator said Monday that it plans to offer 37.5 million shares priced between $15 and $17 per share. At the top end of the range, the offering would raise $637.5 million. Shares of Valeant Pharmaceuticals International Inc. are falling more than 6 percent in Monday's trading following news that the U.S. Food and Drug Administration has failed to approve the Canada-based company's Duobrii lotion for the treatment of plaque psoriasis. Ortho Dermatologics, a division of Valeant Pharmaceuticals, said it has received a Complete Response Letter or CRL from the FDA.
Follow RTT